12/31/2012
[ACCESSWIRE]
Bioniche Life Sciences Inc. is a Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing world-wide of proprietary and innovative products for animal and human health markets. This research-based, technology-driven company has three operating divisions:
Animal Health; Human Health; and Food Safety.
Bioniche is regaining the global rights for
Urocidin™ from Endo Pharmaceuticals, a subsidiary of Endo Health Solutions. After the discontinuation of an Endo-administered second Phase III clinical trial with
Urodicin™ in non-muscle-invasive bladder cancer, the companies have agreed that the path forward is for the global rights for
Urodicin™ to be returned to Bioniche. Endo will receive a royalty on future revenue.
Read more on this development here:
Bioniche eResearch posts all its reports and articles on its website,
eresearch.ca, and subscription is FREE.
eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.
Contact:
eResearch: Bob Weir, CFA, Director of Research
Telephone: (416) 703-6258 Ext 221; E-mail: bweir@eresearch.ca
Leave a comment...
*